Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)

Jeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L van Montfoort, Sophie Hackinger, Linde M Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W van de Kamp, Kees Hendricksen, Jeantine M de Feijter, Thierry N Boellaard, Richard P Meijer, Antoine G van der HeijdenNitzan Rosenfeld, Bas W G van Rhijn, Greg Jones*, Michiel S van der Heijden*

*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (Nature Medicine, (2023), 29, 3, (588-592), 10.1038/s41591-022-02199-y)'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science